Skip to main content

Hologic, Inc. (HOLX)

NASDAQ: HOLX · Delayed Price · USD
77.63 0.48 (0.62%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap19.68B
Revenue (ttm)5.66B
Net Income (ttm)2.04B
Shares Out256.23M
EPS (ttm)7.81
PE Ratio9.95
Forward PE17.21
Dividendn/a
Ex-Dividend Daten/a
Volume2,877,354
Open76.99
Previous Close77.15
Day's Range76.61 - 77.96
52-Week Range60.10 - 85.00
Beta1.17
AnalystsBuy
Price Target85.50 (+10.1%)
Est. Earnings DateNov 3, 2021

About HOLX

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fus...

IndustryHealth Care Equipment & Supplies
IPO DateJun 21, 1990
CEOStephen MacMillan
Employees5,814
Stock ExchangeNASDAQ
Ticker SymbolHOLX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for Hologic stock is "Buy." The 12-month stock price forecast is 85.50, which is an increase of 10.14% from the latest price.

Price Target
$85.50
(10.14% upside)
Analyst Consensus: Buy

News

Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know

Hologic (HOLX) closed the most recent trading day at $77.62, moving -0.55% from the previous trading session.

4 days ago - Zacks Investment Research

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

Hologic (HOLX) closed the most recent trading day at $79.95, moving -0.98% from the previous trading session.

1 week ago - Zacks Investment Research

Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

2 weeks ago - Business Wire

Hologic (HOLX) Up 5.7% Since Last Earnings Report: Can It Continue?

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

10 Best Stocks to Buy if ESG Investing Is Your Thing

If you're into ESG investing and are looking for stocks to buy, Morningstar created a portfolio of ESG mutual funds. Here are 10 solid ideas.

3 weeks ago - InvestorPlace

Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage

Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.

Other symbols:ANTM
3 weeks ago - Zacks Investment Research

A Quality Exec Comp Plan Lowers The Risk Of Investing In Hologic

Overall, nine out of the 15 Exec Comp Aligned with ROIC Stocks outperformed the S&P 500 from July 15, 2021 through August 11, 2021.

3 weeks ago - Forbes

Anthem, Nation's Second Largest Health Plan, Now Covers Hologic's Acessa Procedure as a Treatment for Uterine Fibroids

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United Sta...

3 weeks ago - Business Wire

Buys Dominate Robert Olstein's 2nd-Quarter Portfolio

Olstein Capital Management founder and Chief Investment Officer Robert Olstein (Trades, Portfolio) released his firm's second-quarter portfolio earlier this week.

Other symbols:DINDISCKLUVREYNTKRWGO
1 month ago - GuruFocus

Covid testing remains 30 percent of Hologic business: CEO

Hologic CEO Steve MacMillan joins Closing Bell to discuss the company's recent earnings and how persistent Covid testing might continue to be as a major part of Hologic's business. MacMillan also explai...

1 month ago - CNBC Television

Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull

Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.

1 month ago - Zacks Investment Research

Hologic (HOLX) Q3 Earnings and Revenues Top Estimates

Hologic (HOLX) delivered earnings and revenue surprises of 19.82% and 12.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Hologic Q3 Earnings

Shares of Hologic (NASDAQ:HOLX) increased after the company reported Q3 results. Quarterly Results Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.

1 month ago - Benzinga

Hologic Announces Financial Results for Third Quarter of Fiscal 2021

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2021

1 month ago - Business Wire

Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More

The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other symbols:ABTALGNDGXIARTTMO
1 month ago - Zacks Investment Research

A Trio of High Return Non-Cyclical Stock Picks

Investors may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are doubling the 20-year high quality...

Other symbols:CIGSFM
1 month ago - GuruFocus

Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings

The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.

1 month ago - Zacks Investment Research

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recom...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #CDC--New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs)

1 month ago - Business Wire

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.

1 month ago - Zacks Investment Research

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Hologic (HOLX) Gains As Market Dips: What You Should Know

Hologic (HOLX) closed at $70.37 in the latest trading session, marking a +1.19% move from the prior day.

2 months ago - Zacks Investment Research

Will Hologic Stock Grow Further After A 7% Rise In A Month?

The stock price of Hologic, a medical devices company focused on women's health, has seen a 7% rise over the last twenty-one trading days, while it is up just 12% over the last year. Hologic has benefit...

2 months ago - Forbes

Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark

Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.

2 months ago - Zacks Investment Research

European OK's Use Of Saliva Samples With Hologic's Aptima COVID-19 Test

Hologic Inc (NASDAQ: HOLX) has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe.  The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen'...

2 months ago - Benzinga

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

2 months ago - Business Wire